cCalculated with noninsulin antidiabetic drugs (NIAD) market volume (previously GLP-1) to prepare for RYBELSUS® access calculations. Sources: Data from MMIT Formulary bridge. October 2022 Nomenclature, and Xponent PlanTrak using week-ending 11/11/2022; only considers bridged volume; excludes cash and mail order data; based on full DCS/EDCS/CARD/OCS IC universe (Targets + Non-Targets). Unrestricted defined as Preferred + Covered.
dNovo Nordisk defines formulary coverage as Preferred, Covered, or Covered with Restrictions. Coverage status and tier vary by plan and are subject to change. Please check directly with the health plan to confirm coverage for individual patients.
ePlan data based on number of pharmacy lives as reported by Managed Markets Insight & Technology, LLC (current as of October 2022). Applies to commercial business only. Formulary status is subject to change. Because formularies do change, and many health plans offer more than one formulary, please check directly with the health plan to confirm coverage for individual patients. 2022 Managed Markets Insight & Technology, LLC.